Company’s Research Initiative Recognized as Novel, Innovative Approach to Deliver More Personalized Dialysis Treatment
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that a project featuring the Tablo™ Hemodialysis System has been selected as a winner of the KidneyX Redesign Dialysis Competition. Outset’s winning concept seeks to couple data from Tablo’s unique set of sensors and automation capabilities with physiologic data from the patient to deliver personalized dialysis treatments, ultimately improving outcomes for patients.
The KidneyX Redesign Dialysis Competition is a partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease, a space that has been historically underfunded despite a growing patient population and poor patient outcomes, including high mortality and low quality of life. These sub-optimal outcomes are due in part to dialysis treatment decisions driven by incomplete, imprecise physiologic measurements and a one-size-fits-all approach to treatment planning. Tablo has a proprietary suite of sensors and data sets that can allow it to merge data from the machine and the patient in order to automatically adjust treatment parameters and customize therapy to an individual patient’s needs, all without interrupting clinic workflow.
Read More: https://www.businesswire.com/news/home/20190429005751/en/Outset-Medical-Announced-KidneyX-Award-Winner-U.S./?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
Outset Medical Announced a KidneyX Award Winner by U.S. Department of Health and Human Services and the American Society of Nephrology
Via: The Times-News
The Centers for Disease Control and Prevention reports that nearly 800,000 people in the United States have suffered strokes. Stroke Awareness Month, which occurs in May, is quickly approaching, which makes this a good time to discuss the medical advances in this area. Thankfully, the medical field is rapidly advancing, and new techniques and procedures are created every year. Transcarotid artery revascularization (TCAR) is one such procedure that can change the lives of patients at risk for stroke.
Shares of Silk Road Medical (SILK) popped more than 80% on Thursday with an initial public offering that drew heavy interest from investors. The Silk Road Medical IPO raised $120 million.
SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk Road Medical. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Silk Road Medical’s common stock is expected to begin trading on The Nasdaq Global Market on April 4, 2019, under the ticker symbol “SILK”. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silk Road Medical, are expected to be approximately $120 million. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares. The offering is expected to close on April 8, 2019, subject to the satisfaction of customary closing conditions.
Medical device company Silk Road Medical (SILK) priced its initial public offering at 20 a share, at the high end of its recently raised expected range. The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating. Silk Road stock will start trading Thursday.
Silk Road Medical, which sells medical devices to treat carotid artery disease, announced terms for its IPO on Monday.
Via: MedTech Dive
Silk Road Medical, which sells medical devices used in TCAR for the treatment of carotid artery disease, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
Tepha Inc. Announces Initiation of Clinical Evaluation of P4HB™ Regenerative Scaffold for Stress Urinary Incontinence
Via: PR Newswire
LEXINGTON, Mass., Feb. 27, 2019 /PRNewswire/ -- Tepha Inc. announced today the initiation of a pilot clinical evaluation of the Company's P4HB regenerative polymer scaffold for the surgical treatment of stress urinary incontinence (SUI). The study was initiated in Cape Town, South Africa in partnership with the Pelvic Floor Foundation of South Africa ("PFFSA") and the University of Cape Town. The first procedures were performed by co-principal investigators, Dr. Stephen Jefferyof the University of Cape Town and Professor Jan-Paul Roovers of the Academic Medical Center, Amsterdam, The Netherlands. The Cape Town SUI study represents the first clinical application of Tepha's P4HB polymer technology in the field of urogynecology. Based in Lexington, MA, Tepha is the pioneer developer and exclusive supplier of the P4HB polymer for medical applications that include hernia repair, plastic surgery, tendon & ligament repair, and wound closure.
After winding down its consumer-oriented operations last July, mental health startup Lantern has partnered with larger mental health providers to license its IP. In addition to licensing its IP to Omada Health, Lantern has licensed its tech to Spring Health, Ginger and two others.